CANTEX PHARMACEUTICALS, INC.
Small molecule therapeutics for cancer and infectious diseases
- Sector
- Biotech
- Headquarters
- WESTON, FL
- Latest Form D
- $700K, Feb 2013
- Total capital
- $5.1M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $5.1M
- 2 Form D · last Feb 2013
- 164 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 6
- 34 pending · first 2016
- Rank in peer group#245 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 2nd filing$700K
- Private capital raisedForm D · SEC · 1st filing$4.4M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#245 · top 17%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Stephen G. MarcusResearcherExecutive Officer, DirectorLinked by 4 patents
- Christopher A. KroegerDirectorNamed in SEC Form D filings
- Claude G. BertrandExecutive OfficerNamed in SEC Form D filings
- Neil A. FlanzraichExecutive Officer, DirectorNamed in SEC Form D filings
- Todd C. BradyDirectorNamed in SEC Form D filings
What it has protected
USPTO · 6 granted of 40- PendingTreatment Of GlioblastomaUSPTOApplication 18534470
- GrantedTreatment Of GlioblastomaUSPTOUS 11,648,235
- PendingTreatment Of MyelosuppressionUSPTOApplication 17550942
Show all 40 patent records
- Treatment Of GlioblastomaJul 4, 2024 · Application 18534470Pending
- Treatment Of GlioblastomaMay 16, 2023 · US 11,648,235Granted
- Treatment Of MyelosuppressionNov 10, 2022 · Application 17550942Pending
- Treatment Of Acute Myeloid Leukemia With Hypomethylating Agents And 2-O, 3-O Desulfated HeparinoidsFeb 24, 2022 · Application 17519298Pending
- Treatment Of MyelosuppressionJan 25, 2022 · US 11,229,664Granted
- Disulfiram And Metal Salt Staggered Oral Dosing Regimen And Staggered-release Oral Unit Dosage FormsFeb 2, 2021 · US 10,905,661Granted
- Disulfiram And Metal Salt Staggered Oral Dosing Regimen And Staggered-release Oral Unit Dosage FormsDec 24, 2020 · Application 17013352Pending
- Treatment Of Cancers And Hematopoietic Stem Cell Disorders Privileged By CXCL12-CXCR4 InteractionJul 30, 2020 · Application 16846191Pending
- Disulfiram And Metal Salt Staggered Oral Dosing Regimen And Staggered-release Oral Unit Dosage FormsJun 18, 2019 · US 10,322,096Granted
- Treatment Of Myelodysplastic Syndromes With 2-O And, Or 3-O Desulfated HeparinoidsJan 17, 2019 · Application 16041444Pending
- Treatment Of MyelosuppressionOct 18, 2018 · Application 15923470Pending
- Treatment Of Myelodysplastic Syndromes With 2-O And,or 3-O Desulfated HeparinoidsAug 21, 2018 · US 10,052,346Granted
- Methods Of Treating Traumatic Brain Injury And SequelaeApr 20, 2017 · Application 15294689Pending
- Multivalent Cation Formulations Of Partially Desulfated HeparinsApr 6, 2017 · Application 15126289Pending
- Methods Of Treating And Preventing Radiation DamageOct 6, 2016 · Application 15031248Pending
- Adoptive Cell Transfer MethodsAug 25, 2016 · Application 15044646Pending
- Treatment Of MyelosuppressionJul 28, 2016 · Application 15001773Pending
- Treatment Of MyelosuppressionMar 1, 2016 · US 9,271,999Granted
- Methods of treating traumatic brain injury and sequelaeApplication 62244125Pending
- Adoptive Cell Transfer MethodsApplication 62200504Pending
- Treatment Of Cancers Privileged By CXCL12-CXCR4 InteractionApplication 62181513Pending
- Multivalent Cation Formulations Of Partially Desulfated HeparinsApplication PCTUS2015021068Pending
- Treatment Of Cancers Capable Of Migrating To Or Residing In Privileged Anatomic SitesApplication 62117409Pending
- Hematopoietic Stem Cell TransplantationApplication 62117417Pending
- Methods Of Treating And Preventing Radiation DamageApplication PCTUS2014061634Pending
- Multivalent Cation Formulations Of Partially Desulfated HeparinsApplication 61954374Pending
- Treatment Of MyelosuppressionApplication PCTUS2013031053Pending
- Treatment Of MyelosuppressionApplication 61724836Pending
- Treatment Of MyelosuppressionApplication 61702207Pending
- Use Of Inhibitors Of Receptor For Advanced Glycation Endproducts (rage) For The Treatment Of Inflammatory DisordersApplication PCTUS2024050903Pending
- Use Of Inhibitors Of Receptor For Advanced Glycation Endproducts (rage) For The Treatment Of Inflammatory DisordersApplication 19528054Pending
- Treatment For Solid TumorsApplication PCTUS2024027112Pending
- Treatment Of Immunologically Cold Solid TumorsApplication PCTUS2023086545Pending
- Treatment Of GlioblastomaApplication PCTUS2023086548Pending
- Use Of Inhibitors Of Receptor For Advanced Glycation Endproducts (rage) For The Treatment Of Inflammatory DisordersApplication 63590284Pending
- Treatment Of GlioblastomaApplication 18296740Pending
- Treatment Of Immunologically Cold Solid TumorsApplication PCTUS2022082659Pending
- Disulfiram And Copper Salt Dosing RegimenApplication PCTUS2017061362Pending
- Disulfiram And Metal Salt Staggered Oral Dosing Regimen And Staggered-release Oral Unit Dosage FormsApplication PCTUS2017058358Pending
- Disulfiram And Copper Staggered Oral Dosing Regimen And Staggered-release Oral Unit Dosage FormsApplication 62550500Pending
Related companies, and why
- NEYROBLASTGX LLCSimilar federal contract value in Biotech · null in contracts
- Eumentis Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Perfuse Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Swan NeuroTech, Inc.Similar federal contract value in Biotech · null in contracts
- DalCor Pharmaceuticals US, LLCSimilar federal contract value in Biotech · null in contracts
- AMARIN CORP PLC\UKSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .